REV-ERBs agonist SR9009 inhibits liver fibrosis progression in a MASH fibrosis model invivo.

ABSTRACT: To explore the CC as a therapeutic target for MASH-induced fibrosis, we studied whether SR9009, a pharmacological activator of REV-ERBα, modulates fibrosis in CDA-HFD fed C57Bl/6J mice, a state-of-the-art model for MASH fibrosis

ORGANISM(S): Mus musculus

PROVIDER: GSE272293 | GEO | 2026/07/17

REPOSITORIES: GEO